跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
T-102
首页
药物
T-102
T-102
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers
申请人: IMMATICS BIOTECHNOLOGIES GMBH
优先权: 2020
CN
US
6 件公开
Lipid nanoparticles and application thereof in preparation of CAR-T cells
申请人: SHANGHAI JILIANG MEDICAL ENG CO LTD
优先权: 2024
CN
T-CELL RECEPTOR-PEPTIDE INTERACTION PREDICTION FOR MEDICAL DECISION MAKING
申请人: NEC LAB AMERICA INC
优先权: 2024
WO
Integrated process for capturing carbon dioxide and preparing dimethyl carbonate
申请人: UNIV CHINA MINING & TECHNOLOGY
优先权: 2023
CN
一种肾癌预后标志物TYMP及TYMP抑制剂的应用
申请人: 中国人民解放军总医院第三医学中心
优先权: 2024
CN
SURFACE-MODIFIED ZINC OXIDE PARTICLES, DISPERSION SOLUTION, AND COSMETIC
申请人: SUMITOMO OSAKA CEMENT CO LTD
优先权: 2020
US
2 件公开
ADENO-ASSOCIATED VIRUS CAPSID PROTEIN MUTANT, PACKAGING SYSTEM, RECOMBINANT VIRUS, AND MEDICAL USES
申请人: NANJING UNIVERSITY
优先权: 2025
WO
Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4
申请人: SKERRA ARNE
优先权: 2007
US
2 件公开
药物
反馈